INKTMEDIUM SIGNALOPERATIONAL10-K

INKT expanded its clinical focus to include critical pulmonary immune failure while advancing its engineered iNKT cell pipeline with new CAR-iNKT candidates.

The company has broadened its therapeutic scope beyond oncology to include severe respiratory conditions, potentially expanding its addressable market. The addition of specific CAR-iNKT programs (MiNK-215 and MiNK-413) indicates pipeline advancement, though the company remains in early development stages with continued losses.

Comparing 2026-03-31 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

INKT's financial position shows mixed signals with current liabilities substantially higher at $13.0M from $7.0M, though operating cash burn improved modestly to -$5.9M from -$9.6M. Net losses increased to -$12.5M from -$10.8M, while the company reduced capital expenditures significantly to $74K from $250K. The overall picture reflects a development-stage biotech managing cash burn while scaling back capital investments.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+87.2%
$7.0M→$13.0M

Current liabilities surged 87.2% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-70.6%
$250K→$74K

Capex reduced 70.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+38%
-$9.6M→-$5.9M

Operating cash flow surged 38% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+27.4%
-$19.6M→-$14.2M

Equity base grew 27.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
-15.9%
-$10.8M→-$12.5M

Net income declined 15.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-12%
-$11.3M→-$12.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-18
ADDED
Words such as could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will, potential, opportunity, future and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Amid a broader industry renaissance in innate immunity highlighted by surging investment and clinical activity in NK, T, and iNKT-based therapies iNKT cells represent a distinct T cell ( T ) population that uniquely bridges innate and adaptive immunity.
They combine durable memory responses characteristic of adaptive T cells with rapid, MHC-independent rapid cytolytic capabilities of natural killer ("NK") cells.
This dual functionality enables direct tumor killing via CD1d and stress ligands, potent orchestration of the tumor microenvironment through activation of dendritic cells and NK cells, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function all while naturally suppressing graft-versus-host disease ("GvHD").
These indications include but are not limited critical pulmonary immune failure (including severe hypoxemic respiratory failure / pneumonia), GvHD, solid tumor cancers, and other severe immune-related diseases.
+7 more — sign up free →
REMOVED
Exhibits, Financial Statement Schedules 87 Item 16 Form 10-K Summary 89 i Note Regarding Forward Looking Statements This Annual Report on Form 10-K and other written and oral statements we make from time to time contain forward-looking statements.
You can identify these forward-looking statements by the fact they use words such as could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will, potential, opportunity, future and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.
Certain forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts.
These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions.
iNKT cells represent a distinct T cell population, combining durable memory responses with the rapid cytolytic capabilities of natural killer ("NK") cells.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →